| Previous close | 2.3000 |
| Open | 2.5500 |
| Bid | 2.4500 |
| Ask | 2.9000 |
| Strike | 2.50 |
| Expiry date | 2024-06-21 |
| Day's range | 2.5000 - 2.6700 |
| Contract range | N/A |
| Volume | |
| Open interest | 106 |
GlobeNewswireCenters for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinical trial results and real-world use treating wartime trauma injuries in Ukraine – DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantabl
Simply Wall St.This Is Why Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Looks Appropriate
Key Insights Humacyte to hold its Annual General Meeting on 11th of June Salary of US$603.8k is part of CEO Laura...
GuruFocus.comInsider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)
On May 31, 2024, Heather Prichard, Chief Operating Officer of Humacyte Inc (NASDAQ:HUMA), sold 191,511 shares of the company, according to the SEC Filing.
